Recipient:Cardinal Enterprises, Inc Product: drug products. Date: 12/1/2007 This inspection revealed significant deviations from Current Good Manufacturing Practice (cGMP) Regulations (Title 21, Code of Federal Regulations (21 “CFR), Parts 210 and 211). These deviations cause the drug products manufactured at this facility to be adulterated within the meaning of Section 501(a)(2)(B) of the Federal Food,...Read More